
Bansal Pharma Limited
About Bansal Pharma Limited
Data last updated:
Bansal Pharma Limited is a public limited company based in Thane, Maharashtra, India. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 11 September 1997 and has been in existence for over 29 years.
The company is registered with the Registrar of Companies (ROC), Mumbai, under CIN U24200MH1997PLC110599. Its GSTIN is 27AAACB5100F2ZB (Maharashtra). The company holds 2 GST registrations, of which 1 is active.
The company has an authorised share capital of ₹10 Lakh and a paid-up capital of ₹10 Lakh. It is led by directors including Sajankumar Rameshwarlal Bajaj and Anil Champalal Jain.
Its last annual general meeting (AGM) was held on 30 September 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at 606 Bhoomi Velocity Infotech Park, Thane, Maharashtra.
As per the financials filed for FY 2024, the company reported a revenue of ₹64,110, a decline of 71% compared to the previous year. For the same year it recorded a net loss of ₹70,556 (net margin -110.1%) and EBITDA of ₹8,410 (EBITDA margin 13.1%). Revenue has declined at a compounded annual rate (CAGR) of 51% over three years and 52% over five years.
As per MCA filings, the company has satisfied charges of ₹2.78 Cr on record. Court records list 2 cases involving the company, including 2 filed by the company.
The current compliance status is marked as compliant by the Registrar of Companies.
Company details
Contact details
Bansal Pharma Limited's registered office is in Thane, Maharashtra. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Registered Address602 – 606 Bhoomi Velocity Infotech Park Plot No.B – 39 39A 39A/1rd No.23 Wagle In, D. Estate, Thane, Maharashtra, India – 400604
- IndustryPharma, Drug Formulation & Development
To see the full contact details of Bansal Pharma Limited, buy the company report.
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
Financials of Bansal Pharma Limited
FY 2025 filings availableBansal Pharma Limited reported revenue of ₹64,110 (down 71% YoY) for FY 2024.
Compounded Annual Growth Rate (CAGR)
Revenue has declined at a compounded annual rate (CAGR) of 52% over five years, including a 71% fall in the latest year. EBITDA fell 3% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary
| Metrics | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | |||||
| Other Income | |||||
| Total Revenue | |||||
| Cost of Materials Consumed | |||||
| Employee Benefit Expense | |||||
| Finance Costs | |||||
| Depreciation and Amortisation | |||||
| Other Expenses | |||||
| Total Expenses | |||||
| EBITDA | ₹8,410 | ||||
| Profit Before Tax | |||||
| Tax Expense | |||||
| Net Profit (PAT) | -₹70,556 | ||||
| Balance Sheet | |||||
| Share Capital | |||||
| Reserves and Surplus | |||||
| Net Worth (Total Equity) | |||||
| Long-term Borrowings | |||||
| Short-term Borrowings | |||||
| Trade Payables | |||||
| Total Liabilities | |||||
| Fixed Assets | |||||
| Investments | |||||
| Inventories | |||||
| Trade Receivables | |||||
| Cash and Bank Balance | |||||
| Total Assets | |||||
Financial Ratios
| Metrics | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | 13.1% | ||||
| Net Profit Margin | -110.1% | ||||
| Return on Equity (ROE) | |||||
| Return on Capital Employed (ROCE) | |||||
| Return on Assets (ROA) | |||||
| Liquidity and Debt | |||||
| Current Ratio | |||||
| Quick Ratio | |||||
| Debt-to-Equity Ratio | |||||
| Interest Coverage Ratio | |||||
| Efficiency and Growth | |||||
| Asset Turnover | |||||
| Receivable Days | |||||
| Payable Days | |||||
| Inventory Days | |||||
| Revenue Growth | |||||
| Net Profit Growth | |||||
To see the full financial statements and ratios of Bansal Pharma Limited, buy the company report.
Board of directors of Bansal Pharma Limited
Bansal Pharma has 3 current directors and 4 former directors. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Sajankumar Rameshwarlal Bajaj Also directs: Bajaj Health and Nutritions LLP, Saanjaan Equipments LLP, Bajaj Healthcare Limited and 4 more | Director | 01 Apr 1998 | 28 Years 7 Months | Current |
| Anil Champalal Jain Also directs: Saanjaan Equipments LLP, Bajaj Healthcare Limited, Bajaj Sindhudurg Rice Mills Limited and 2 more | Director | 31 Jul 1999 | 27 Years 3 Months | Current |
| Namrata Sajankumar Bajaj Also directs: Bajaj Health and Nutritions LLP, Bajaj Healthcare Limited, Bajaj Sindhudurg Rice Mills Limited and 3 more | Director | 01 Apr 2025 | 1 Years 7 Months | Current |
Peer comparison
Bansal Pharma Limited is compared with the 3 companies closest to it by revenue in the Pharma industry (Pharma Retail and Distribution), with the same principal business activity (wholesale trading), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Gentech Global Pharma Private Limited | ₹64,221 (FY 2025) | Delhi, India | ||||
| Bansal Pharma Limitedthis company | ₹64,110 (FY 2024) | -₹70,556 | -110.1% | -71.0% | Thane, Maharashtra, India | |
| Kite Medica Private Limited | ₹63,523 (FY 2025) | -100.0% | Mumbai, Maharashtra, India | |||
| Wellness Marketing Exi Private Limited | ₹62,820 (FY 2025) | -91.0% | Delhi, India |
To see the full peer comparison of Bansal Pharma Limited, buy the company report.
Auditor
Bansal Pharma Limited is audited by PARESH RAKESH & ASSOCIATES for the financial year 2023.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| PARESH RAKESH & ASSOCIATES | FY 2023 | 119728W |
Shareholding
The shareholding of Bansal Pharma Limited is on record for 5 financial years, the latest being FY 2023, split between promoters, domestic institutions, foreign institutions, public shareholders and others.
| Shareholder category | FY 2023 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|
| Promoters | |||||
| Domestic institutional investors (DII) | |||||
| Foreign institutional investors (FII) | |||||
| Public | |||||
| Others |
To see the full shareholding pattern of Bansal Pharma Limited, buy the company report.
Charges & borrowings
| Date | Charge ID | Lender | Amount | Status | Modified or satisfied on |
|---|---|---|---|---|---|
| 20 Feb 2004 | 90148579 | The Saraswat Co-Operative Bank Ltd | ₹75 Lakh | Satisfied | |
| 04 Nov 1999 | 90147367 | The Saraswat Co-Operative Bank Ltd | ₹3.3 Lakh | Satisfied | |
| 23 Aug 1999 | 90142508 | Corporation Bank | ₹1 Cr | Satisfied | |
| 23 Aug 1999 | 90147332 | Corporation Bank | ₹1 Cr | Satisfied |
To see the full charge records of Bansal Pharma Limited, buy the company report.
Total charge records: 4 View all charges
Legal cases
Bansal Pharma Limited has 2 court cases on record: 2 filed by Bansal Pharma. All cases are disposed.
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| District courts | 1 | 0 | 0 |
| High courts | 1 | 0 | 0 |
Cases on record (2 of 2)
| Court | Type of case | Party | Status |
|---|---|---|---|
| High Court, GUJARAT | Court case (COMP) | Filed by the company against Ambalal Sarabhai Enterprises Ltd. | Disposed |
| District court, Mumbai CMM Courts, Maharashtra | Court case (Summons cases SS) | Filed by the company against Ms. Jin Pharmachem and 1 other | Disposed |
To see the full case history of Bansal Pharma Limited, buy the company report.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
MSME payment delays
No delayed payments to MSME suppliers are on our record for Bansal Pharma Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.
GST
Bansal Pharma has 2 GST registrations: 1 active and 1 cancelled or inactive.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 27AAACB5100F2ZB | Maharashtra | Active | 01 Jul 2017 |
To see the full GST registrations and return filing status of Bansal Pharma Limited, buy the company report.
Recent activity
Bansal Pharma Limited has 7 board changes on record since 1998: 3 appointments and 4 cessations. The latest: Namrata Sajankumar Bajaj ceased to be Additional Director on 29 Sep 2025.
7 earlier events are in the company report.
Frequently asked questions
Bansal Pharma is an active public limited company based in Thane, Maharashtra, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 11 September 1997 (29+ years old) and is registered under CIN U24200MH1997PLC110599.
Bansal Pharma has 3 current directors:
- Sajankumar Rameshwarlal Bajaj - Director
- Anil Champalal Jain - Director
- Namrata Sajankumar Bajaj - Director
The latest financial statements of Bansal Pharma on record with the MCA are for the year ended 31 March 2025. Its last annual general meeting was held on 30 September 2025. Year-wise statements from 2015 are in the company report.
The GSTIN of Bansal Pharma is 27AAACB5100F2ZB, registered in Maharashtra. The company has 2 GST registrations in all, of which 1 is active and 1 is cancelled or inactive.
The CIN (Corporate Identification Number) of Bansal Pharma is U24200MH1997PLC110599. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Bansal Pharma has 2 court cases on record: 2 filed by the company. Most are in the district courts.
Bansal Pharma was incorporated on 11 September 1997, making it 29+ years old. It is registered with the Registrar of Companies, Mumbai.
The peers of Bansal Pharma by revenue are Gentech Global Pharma Private Limited, Kite Medica Private Limited, Wellness Marketing Exi Private Limited, all in the Pharma industry (Pharma Retail and Distribution), with the same principal business activity (wholesale trading).
Namrata Sajankumar Bajaj ceased to be Additional Director on 29 Sep 2025. Dhananjay Hatle Sabaji ceased to be Director on 05 Jun 2025. Namrata Sajankumar Bajaj was appointed as Director on 01 Apr 2025. Bansal Pharma has 7 board changes on record in total.
The registered office of Bansal Pharma is at 602 – 606 Bhoomi Velocity Infotech Park Plot No.B – 39 39A 39A1rd No.23 Wagle In, D. Estate, Thane, Maharashtra, India – 400604.
Bansal Pharma operates in the pharma industry, in the drug formulation and development segment.

